Abstract
Sacubitril/valsartan is a new drug indicated to treat adult patients with symptomatic heart failure with reduced ejection fraction. It is a combination of the neprilysin inhibitor (neprilysin is an enzyme degrading natriuretic and other vasoactive peptides) sacubitril and the angiotensin II receptor blocker valsartan.
Efficacy of this drug has been shown in PARADIGM-HF, a multicentre randomized, double-blind study. The study evaluated therapy with the above sacubitril/valsartan in comparison with enalapril and documented a 20% reduction in cardiovascular mortality, 21% reduction of risk of hospital admission for heart failure, and 16% reduction in overall mortality.
These results were obtained in patients who tolerated sacubitril/valsartan well and with no severe adverse effects. This therapy thus appears as appropriate replacement of the current employed standard therapy with renin-angiotensinaldosterone system inhibitors.